Phase II study; open recruitment, multicentrique. The aim of this clinical research is to evaluate faisability and toxicity of the per-operative radiotherapy using PAPILLON + TM device for localized breast cancers patients over 65 years.

Inclusion Criteria:

• Patient with invasive ductal adenocarcinoma <=2cm, evaluate on all radiological exams;
• Women aged 65 years or older (patients 65 years of age in the year may be included);
• Grade 1 or 2 unifocal adenocarcinoma, all index KI67, positive HR, negative HER2 status;
• T0 or T1, N0 radio-clinic;
• Operable patient with breast volume compatible with conservative surgery;
• Patient with prior malignancy or other concurrent malignancies are eligible, including bilateral breast cancer
• Patients who have been made aware of the information sheet and have given their written signed informed consent;
• Patients benefitting from social health insurance coverage

Exclusion Criteria:

• Age less than 65 years (except if 65 years obtained during the year)
• Patient with an exclusive in situ carcinoma
• Patient with lymphatic invasion / peri-nerve involvement / vascular emboli
• Patient with a lobular adenocarcinoma
• Patient with metastatic disease
• Multifocal tumor
• Patient with grade 3 or N+ disease
• N1 proved by ultrasound guided
• patient unable to express her consent
• Patient deprived placed under the authority of a tutor
• Female patients who are pregnant or breastfeeding
• Vulnerable patient: as defined in article L1121-5 à -8